Porton Advanced Partners with Ascist Biotech to Accelerate IND Submission for Adult Pancreatic Progenitor Cell Therapy in Diabetes
Porton Advanced Secures FDA Acceptance for hUC-MSC Exosome DMF
Porton Advanced Supports LianLi Zhongda’s LM101 Injection in Securing IND Clearance, Marking Another Milestone in End-to-End CDMO Track Record
Porton Advanced and Yeasen Biotechnology Forge Strategic Partnership to Strengthen CGT Supply Chain Diversification and Collaborative Innovation
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
